Adding concurrent chemotherapy to postoperative radiotherapy improves locoregional control but Not overall survival in patients with salivary gland adenoid cystic carcinoma—a propensity score matched study

Table 3 Treatment outcomes of patients with salivary gland adenoid cystic carcinoma bearing adverse pathological risk factors in the propensity score-matched cohort, treatment with PORT versus POCRT

		LRC			DMFS			DFS			OS			ORPFS
Variable	N	5-yr	8-yr	P	5-yr	8-yr	P	5-yr	8-yr	P	5-yr	8-yr	P	5-yr	8-yr	P
Stage III-IV
PORT	15	70.6	49.4	.040	47.7	47.7	.601	40.9	32.7	.963	77.8	60.0	.705	62.2	43.6	.017
POCRT	19	94.4	94.4		43.8	29.2		43.8	29.2		75.9	60.7		92.9	92.9
Margins < 1 mm
PORT	26	73.7	60.5	.011	59.0	59.0	.669	54.3	48.3	.972	86.2	74.1	.894	81.6	68.2	.050
POCRT	28	96.4	96.4		54.5	37.4		54.5	37.4		79.8	71.8		95.5	95.5
Perineural invasion
PORT	24	73.1	58.6	.013	54.5	54.5	.849	49.9	43.7	.857	81.6	69.2	.792	77.2	63.4	.035
POCRT	27	96.2	96.2		52.1	41.7		52.1	41.7		77.2	68.7		95.0	95.0
Bone invasion
PORT	8	87.5	52.5	.425	45.0	45.0	.652	45.0	30.0	.851	72.9	72.9	.220	72.9	43.8	.260
POCRT	11	90.0	90.0		50.5	50.5		50.5	50.5		52.6	52.6		83.3	83.3
Muscle invasion
PORT	11	57.3	43.0	.240	54.5	54.5	.260	43.0	28.6	.608	77.9	48.7	.772	54.5	40.9	.214
POCRT	7	85.7	85.7		19.0	19.0		19.0	19.0		80.0	80.0		83.3	83.3

Data for survival estimates are expressed as percentages
Abbreviations: PORT postoperative radiotherapy, POCRT postoperative chemoradiotherapy, LRC locoregional control, DMFS distant metastasis-free survival, DFS disease-free survival, OS overall survival, ORPFS opioid-requiring pain-free survival

ISSN: 1748-717X